Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced that the FDA cleared the company to proceed with a Phase 3 clinical trial using the investigational EV drug ExoFlo to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19.
Satellite Bio launched Wednesday with $110 million in previously undisclosed Seed and Series A investments led by aMoon Growth.
Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.
Cryoport Inc. appointed creative communications agency Mind+Matter, an Ashfield Health company and part of UDG Healthcare, as the company’s strategic marketing partner to support the rebrand of the entire business alongside a strategic communications plan.
MiMedx Group Inc., an industry leader in utilizing birth tissue as a platform for regenerative medicine, announced the appointment of Phyllis Gardner, M.D. to the Board of Directors.
Regenerative medicine company AVITA Therapeutics Inc. announced the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020.
Vineti and EVERSANA announced a partnership to improve access, affordability and patient support challenges in regenerative medicine.
With $76 million in financing, San Diego-based Autobahn Therapeutics is hitting the ground with a goal of developing regenerative medicines aimed at treating disorders of the central nervous system (CNS).
Cryoport Inc. and EVERSANA announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.
Smith & Nephew Plc will buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing.